Naltrexone treatment for a 3-year-old boy with self-injurious behavior

American Journal of Psychiatry

Volumn 157, Issue 10, 2000, Pages 1574-1582

  White, T ^a   Schultz, S K ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE;

ANAMNESIS; AUTOMUTILATION; CASE REPORT; CHILD; CHILD PSYCHIATRY; CLINICAL EXAMINATION; CONFERENCE PAPER; DRUG RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CASE REPORT; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; FOLLOW-UP STUDIES; HUMAN; MALE; MENTAL RETARDATION; NALTREXONE; NARCOTIC ANTAGONISTS; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME;

EID: 0033810569     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.10.1574     Document Type: Conference Paper

References (121)

1. Functional assessment and intervention in community settings
2. Aversive control of self-injurious behavior in a psychotic boy
3. An analysis of the variables related to self-injurious behavior among institutionalized retarded persons
4. Prevalence of self-injurious behavior in a large state facility for the retarded: A three-year follow-up study
5. A community survey of self-injurious behavior among developmentally disabled children and adolescents
6. The definition taxonomy, epidemiology, and ecology of self-injurious behavior
7. Self-mutilation in schizophrenic children
8. Self-mutilative behavior in verbal and non-verbal schizophrenic children
9. Low-dose naltrexone inhibits pemoline-induced self-biting behavior in prepubertal rats
10. Allocating direct-care resources for treatment of maladaptive behavior: The Staff Intensity Scale
11. The Lesch-Nyhan syndrome
12. Effects of undesirable, competing behaviors on the generalization of adaptive skills: A case study
13. Intensive and long-term treatments for clients with destructive behavior, in Destructive Behavior in Developmental Disabilities
14. Reducing aggressive and self-injurious behavior of institutionalized retarded children through reinforcement of other behavior
15. Restitution: A method of eliminating aggressive-disruptive behavior of retarded and brain damaged patients
16. The elimination of autistic self-stimulatory behavior by overcorrection
17. Clinical evaluation of the Self-Injurious Behavior Inhibiting System (SI-BIS)
18. Manipulation of self-destructive behavior
19. Severe self-injurious behavior: The problem of clinical control
20. Development and maintenance of a behavior modification program for behaviorally retarded institutionalized men
21. Bio-behavioral diagnosis and treatment of self-injury
22. A functionally based approach to the treatment of self-injurious behavior
23. The treatment of self-injurious behavior
24. Pharmacotherapy for self-injurious behavior: Preliminary tests of the D1 hypothesis
25. Clinical trials of D1 and D2 dopamine modulating drugs and self-injury in mental retardation and developmental disability
26. Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation
27. Low-dose haloperidol for stereotypic self-injurious behavior in the mentally retarded
28. Psychopharmacology of self-injurious behavior in the mentally retarded
29. Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation
30. The management of chronic behavior disorders in mentally retarded adults with lithium carbonate
31. Control of gross self-mutilation with lithium carbonate
32. Effect of lithium on disturbed severely mentally retarded patients (letter)
33. Towards a rational drug usage in a state institution for retarded individuals
34. Beta-blockers in the severely and profoundly mentally retarded
35. Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent
36. Tryptophan-trazodone treatment of aggressive behavior
37. Trazodone for aggression in an adolescent with hydrocephalus
38. Prophylactic effect of L-5-hydroxytryptophan on self-mutilation in the Lesch-Nyhan syndrome
39. Serotonergic approaches to the modification of behavior in the Lesch-Nyhan syndrome
40. Lesch-Nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters
41. Fluoxetine treatment of depression and associated self-injury in two adults with mental retardation
42. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: A preliminary study
43. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities
44. Clinical effects of buspirone on intractable self-injury in adults with mental retardation
45. The use of opiate antagonists for recurrent self-injurious behavior
46. Naloxone and self-mutilation
47. Effect of naltrexone upon self-injurious behavior, learning and activity: A case study
48. Naltrexone decreases self-injurious behavior
49. Effects of narcotic antagonists on self-injurious behavior: A single case study
50. Effects of naloxone on self-injurious behavior: A case study
51. Naloxone attenuates self-abusive behavior in developmentally disabled clients
52. Naloxone abolishes self-injuring in a mentally retarded child (letter)
53. Influence of naloxone on brain and behavior of a self-injurious woman
54. Effects of naloxone and naltrexone on self-injury: A double-blind, placebo-controlled analysis
55. Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone
56. An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior
57. Naltrexone in autistic children: An acute open dose range tolerance trial
58. Naltrexone for neurotic excoriations
59. Naltrexone attenuates self-injurious behavior in mentally retarded subjects
60. A case report of naltrexone treatment of self-injury and social withdrawal in autism
61. Initial aggravation of self-injurious behavior in autistic patients receiving naltrexone treatment
62. A synopsis of an open-trial of naltrexone treatment of autism with four children
63. Clinical effects of naltrexone on autistic behavior
64. Cessation of long-term naltrexone therapy and self-injury: A case study
65. Naltrexone in autistic children: Behavioral symptoms and attentional learning
66. Naltrexone has no hepatotoxic effects in a self-injurious patient with chronic hepatitis
67. Opioid antagonist effects on self-injury in adults with mental retardation: Response form and location as determinants of medication effects
68. Naloxone blockade of apomorphine-induced stereotyped behavior
69. Self-injurious behavior as endogenous neurochemical self-administration
70. Drugs and learning in mentally retarded persons
71. Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behavior by influencing D1-dopamine receptor function
72. Opiate mechanisms in self-injury
73. Naltrexone and self-injurious behavior: A retrospective population study
74. Repetitive stereotyped behaviors
75. The motivation of self-injurious behavior: A review of some hypotheses
76. Stress-induced parallel changes in central opioid levels and pain responsiveness in the rat
77. Stress-induced analgesia in humans: Endogenous opioids and naloxone-reversible depression of pain reflexes
78. Surgical stress in humans is accompanied by an increase in plasma beta-endorphin immunoreactivity
79. Physical dependence of opiate-like peptides
80. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers
81. Beta-endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland
82. Differential release of proopiomelanocortin-derived peptides from the human pituitary: Evidence from a panel of two-site immunoradiometric assays
83. Betaendorphin and corticotropin release is dependent on a threshold intensity of running exercise in male endurance athletes
84. Beta-endorphin and ACTH in plasma: Effects of physical and psychological stress
85. Neuroendocrine response to psychological performance testing
86. Long-lasting impairment of neuroendocrine response to psychological stress in heroin addicts
87. Peripheral plasma levels of beta-endorphin in alcoholics and highly trained athletes and the relationship to a measure of central opioid tone
88. Beta-endorphin: Stability, clearance behavior, and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits
89. Peripherally administered betaendorphin increases cerebrospinal fluid endorphin immunoreactivity
90. Causal links between plasma and CSF endorphin levels in stress: Vector-ARMA analysis
91. Neurophysiology and neurochemistry of drug dependence: A review
92. The D2 dopamine receptor gene: A review of association studies in alcoholism and phenotypes
93. Dopamine mechanisms of cocaine addiction
94. A review of the role of anti-opioid peptides in morphine tolerance and dependence
95. Case study: Paradoxical response to naltrexone treatment of self-injurious behavior
96. Deficiency in the opioid hypotheses of self-injurious behavior (comment and discussion)
97. Beta-endorphin disregulation in autistic and self-injurious behavior: A neurodevelopmental hypothesis
98. Endorphin activity in childhood psychosis
99. A possible role of proopiomelanocortin peptides in self-injurious behavior
100. Observations on the neuropsychopharmacology of morphine and morphine-like analgesia
101. Congenital insensitivity to pain, and endogenous morphine-like substances
102. Congenital insensitivity and naloxone
103. Naloxone alters pain perception and somatosensory evoked potentials in normal subjects
104. Interaction of opioid peptide-containing terminals with dopaminergic perikarya in the rat hypothalamus
105. Morphine-dopamine interaction: Ventral tegmental morphine increases nucleus accumbens dopamine release
106. Identification of the opioid receptor types mediating beta-endorphin-induced alterations in dopamine release in the nucleus accumbens
107. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway
108. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence
109. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine
110. Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome
111. Interaction between hypothalamic dopaminergic and opioidergic systems in the photoperiodic regulation of pulsatile luteinizing hormone secretion in sheep
112. Cessation of long-term naltrexone administration: Longitudinal follow-ups
113. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: Double-blind placebo-controlled studies
114. Role for opioid peptides in self-injurious behavior: Dissociation from autonomic nervous system functioning
115. Using analog baselines to assess the effects of naltrexone on self-injurious behavior
116. Dopaminergic mechanisms in self-injurious behavior
117. Self-injurious behaviour and body site preference
118. Endorphins implicated in stereotypies of tethered sows
119. Changes in naloxone and haloperidol effects during the development of captivity-induced jumping stereotypy in bank voles